Listen
Reason for request
Extension of indication
-
Clinical Benefit
| Low |
Low, and provisional pending re-evaluation of gliptins in triple therapy, in combination with insulin when combined insulin/metformin, with diet and exercise, does not provide adequate glycaemic control. |
Clinical Added Value
| no clinical added value |
In triple therapy in combination with insulin, KOMBOGLYZE, a fixed-dose combination of saxagliptin and metformin, does not offer any improvement in actual benefit (IAB V, non-existent) in the treatment of patients with type 2 diabetes in whom combined insulin/metformin, with diet and exercise, does not provide adequate glycaemic control. |
Documents
English version
Contact Us
Évaluation des médicaments
